SWK Holdings Corporation (SWKH) Stock Analysis
DELISTED 2026
What happened to SWK Holdings Corporation (SWKH) stock?
SWK Holdings Corporation (SWKH) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SWK Holdings Corporation (SWKH) trades at $15.90. SWK Holdings Corporation is a specialty finance company focused on providing customized financing solutions to life science companies. Market cap: $192M, Sector: Financial services.
Last analyzed: May 10, 2026Analyst Coverage for SWKH: SWKH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SWKH against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
SWKH: 2/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →SWK Holdings Corporation (SWKH) Financial Services Profile
SWK Holdings Corporation, a specialty finance company, focuses on the healthcare sector, offering tailored financing solutions to life science companies in biotechnology, medical devices, and pharmaceuticals. Operating through Finance Receivables and Pharmaceutical Development segments, SWKH also provides investment advisory services and develops novel formulations via its Peptelligence platform.
What Is the Investment Thesis for SWKH?
SWK Holdings Corporation presents a focused investment opportunity within the specialty finance sector, specifically targeting the healthcare and life sciences industries. With a market capitalization of $192M and a high gross margin of 95.3%, the company demonstrates strong revenue generation capabilities. However, the negative profit margin of -6.2% warrants careful consideration, indicating potential challenges in operational efficiency or increased expenses. Growth catalysts include the expansion of its Peptelligence platform and the out-licensing of its internal product pipeline. The company's low beta of 0.30 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors. Successful execution of its pharmaceutical development strategy and efficient deployment of capital in its finance receivables segment are key to driving future profitability. Investors should monitor the company's ability to manage expenses and improve its bottom-line performance.
Based on FMP financials and quantitative analysis
SWKH Key Highlights
Market capitalization of $192M, reflecting its size within the specialty finance sector.
- Gross margin of 95.3%, indicating strong revenue generation relative to the cost of goods sold.
- Negative profit margin of -6.2%, highlighting potential challenges in operational efficiency or expense management.
- Beta of 0.30, suggesting lower volatility compared to the broader market.
- Operates in two segments: Finance Receivables and Pharmaceutical Development, providing diversification within the healthcare sector.
Who Are SWKH's Competitors?
SWKH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BANX ArrowMark Financial Corp. | $20.70 | +0.95% | $201M | 72 |
| MPV Barings Participation Investors | $16.26 | -0.85% | $175M | 67 |
| GGT The Gabelli Multimedia Trust Inc. | $4.11 | -0.24% | $172M | 68 |
| LIEN Chicago Atlantic BDC, Inc. | $9.74 | +2.53% | $223M | 86 |
| CAGPF Samara Asset Group plc | $2.49 | +0.00% | $228M | 67 |
| HTFC Horizon Technology Finance Corp. | $24.97 | +0.00% | $230M | 75 |
| WHF WhiteHorse Finance, Inc. | $7.26 | +2.98% | $156M | 90 |
| CHECU Chenghe Acquisition III Co. Units | $10.25 | +0.39% | $134M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SWKH's Key Strengths?
Specialized expertise in healthcare finance
- Customized financing solutions
- Proprietary Peptelligence platform
- Established relationships with life science companies
What Are SWKH's Weaknesses?
Negative profit margin
- Small number of employees (24)
- Limited geographic reach
- Reliance on the healthcare sector
What Could Drive SWKH Stock Higher?
Potential out-licensing agreements for products developed through the Peptelligence platform.
- Continued deployment of capital in the Finance Receivables segment.
- Expansion of investment advisory services to institutional clients.
What Are the Key Risks for SWKH?
Financial-distress signal — its Altman Z-Score of -17.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-1.0%) — the business is not currently generating profit on shareholder capital.
- Economic downturn affecting the ability of life science companies to repay financing.
- Regulatory changes in the healthcare industry impacting the profitability of investments.
- Competition from other finance companies offering similar services.
- Negative profit margin impacting overall financial performance.
What Are the Growth Opportunities for SWKH?
- Expansion of the Peptelligence Platform: SWK Holdings can expand its pharmaceutical development capabilities through the Peptelligence platform. By developing and out-licensing novel formulations, the company can generate revenue streams from licensing fees and royalties. The market for novel drug formulations is substantial, driven by the need for improved treatments and patient outcomes. This strategy aligns with the company's focus on innovation and value creation within the healthcare sector. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: SWK Holdings can pursue strategic partnerships and acquisitions to expand its reach and capabilities within the life science finance sector. Collaborating with or acquiring complementary businesses can enhance its service offerings and market presence. The market for life science financing is competitive, and strategic alliances can provide a competitive edge. Timeline: Ongoing.
- Increased Investment in R&D: SWK Holdings can increase its investment in research and development to drive innovation within its Pharmaceutical Development segment. By developing new formulations and treatments, the company can create value for patients and shareholders. The healthcare industry is characterized by constant innovation, and R&D is essential for staying competitive. Timeline: Ongoing.
- Geographic Expansion: SWK Holdings can expand its geographic reach to tap into new markets and opportunities. By offering its financing solutions and pharmaceutical products in international markets, the company can diversify its revenue streams and reduce its reliance on the domestic market. The global healthcare market is vast, and geographic expansion can provide significant growth potential. Timeline: Ongoing.
- Focus on High-Growth Subsectors: SWK Holdings can focus its financing activities on high-growth subsectors within the life science industry, such as gene therapy, personalized medicine, and digital health. These subsectors are experiencing rapid growth and offer significant investment opportunities. By targeting these areas, SWK Holdings can capitalize on emerging trends and generate attractive returns. Timeline: Ongoing.
What Are SWKH's Competitive Advantages?
- Specialized Focus: Focus on the healthcare sector and life science companies provides specialized expertise.
- Customized Solutions: Offers customized financing solutions tailored to the specific needs of its clients.
- Peptelligence Platform: Proprietary Peptelligence platform for pharmaceutical development provides a competitive advantage.
- Established Relationships: Strong relationships with life science companies and institutional investors.
What Does SWKH Do?
Founded in 1996 and headquartered in Dallas, Texas, SWK Holdings Corporation has evolved into a specialty finance company dedicated to the healthcare sector. Originally named Kana Software, Inc., the company rebranded in December 2009 to reflect its strategic shift towards healthcare finance. SWK Holdings operates through two primary segments: Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a diverse range of life science companies, including those in biotechnology, medical devices, medical diagnostics and related tools, animal health, and pharmaceuticals. These solutions cater to companies, institutions, and inventors seeking capital for growth and innovation. The Pharmaceutical Development segment focuses on the development, formulation, manufacturing, and licensing of pharmaceutical products through the Peptelligence platform. SWK Holdings intends to out-license its internal product pipeline, leveraging its proprietary technology to create novel formulations for various treatments. Additionally, SWK Holdings offers non-discretionary investment advisory services, managing separately managed accounts for institutional clients seeking exposure to life science finance.
What Products and Services Does SWKH Offer?
- Provides customized financing solutions to life science companies.
- Offers financing to companies in biotechnology, medical devices, and pharmaceuticals.
- Engages in pharmaceutical development through the Peptelligence platform.
- Develops, formulates, manufactures, and licenses pharmaceutical products.
- Offers non-discretionary investment advisory services.
- Manages separately managed accounts for institutional clients.
- Intends to out-license its internal product pipeline.
How Does SWKH Make Money?
- Generates revenue through interest income from finance receivables.
- Earns fees from investment advisory services.
- Receives licensing fees and royalties from out-licensing pharmaceutical products.
- Engages in pharmaceutical development through the Peptelligence platform.
What Industry Does SWKH Operate In?
SWK Holdings Corporation operates within the asset management industry, specifically focusing on specialty finance within the healthcare sector. The market for healthcare-related financing is driven by the constant need for innovation and expansion in biotechnology, medical devices, and pharmaceuticals. The competitive landscape includes traditional financial institutions, venture capital firms, and other specialty finance companies. SWK Holdings differentiates itself by offering customized financing solutions and leveraging its Peptelligence platform for pharmaceutical development. The industry is subject to regulatory changes, economic cycles, and the overall health of the capital markets.
Who Are SWKH's Key Customers?
- Life science companies in biotechnology, medical devices, and pharmaceuticals.
- Institutions seeking investment opportunities in life science finance.
- Inventors requiring financing for healthcare-related projects.
Forward Outlook
Wall Street analysts project SWK Holdings Corporation revenue of about $38.2M for fiscal 2026, with EPS near $2.10.
SWKH Valuation & Market Position
With a $192M market cap, SWK Holdings Corporation sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for SWK Holdings Corporation stands at -1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 13.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
SWK Holdings Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -17.77 places it in the distress zone, a signal of elevated financial risk.
Company Profile
SWK Holdings Corporation operates in the Asset Management industry within the Financial Services sector. It is headquartered in Dallas, US. The company is led by CEO Jody. D Staggs. SWKH has traded publicly since 1999.
SWKH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in its growth potential.
- Community sentiment has turned increasingly positive, with discussions highlighting innovative product developments and strategic partnerships.
- Market perception is buoyed by recent media coverage showcasing SWK's advancements in its sector, attracting attention from potential investors.
- The company's focus on niche markets has resonated well with investors looking for unique opportunities in a crowded space.
Bear Case
- Concerns have been raised about the company's ability to scale its operations efficiently, leading to skepticism among some investors.
- Recent social sentiment has shown mixed feelings, with a portion of the community expressing doubts about long-term profitability.
- Market developments in competing sectors have raised questions about SWK's market positioning and its ability to maintain competitive advantages.
- Some analysts have pointed to potential regulatory risks that could impact future growth, leading to caution among certain investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SWKH Latest News
No recent news available for SWKH.
Leadership: Jody. D Staggs
CEO
Information on Jody D. Staggs's specific background and career history is not available within the provided context. Without additional data, a detailed biography cannot be accurately constructed. Generally, CEOs of financial services companies have extensive experience in finance, investment banking, or related fields. They often hold advanced degrees in business administration, finance, or economics. Their prior roles typically include leadership positions in financial institutions or investment firms.
Track Record: Information on Jody D. Staggs's specific track record and achievements as CEO of SWK Holdings Corporation is not available within the provided context. Without additional data, a detailed assessment of their performance cannot be accurately constructed. Generally, a CEO's track record is evaluated based on the company's financial performance, strategic decisions, and key milestones achieved under their leadership.
SWK Holdings Corporation Financial Services Stock: Key Questions Answered
What happened to SWK Holdings Corporation (SWKH) stock?
SWK Holdings Corporation (SWKH) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
Can I still buy SWKH shares?
No. SWKH stopped trading on public markets in April 2026, so the shares are not available through a broker. Anything you see quoted for SWKH elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SWKH stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to SWK Holdings Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does SWK Holdings Corporation do?
SWK Holdings Corporation operates as a specialty finance company focused on the healthcare sector. It provides customized financing solutions to life science companies, including those in biotechnology, medical devices, and pharmaceuticals. The company also engages in pharmaceutical development through its Peptelligence platform, developing and out-licensing novel formulations.
What do analysts say about SWKH stock?
Analyst coverage of SWK Holdings Corporation (SWKH) may vary depending on the specific firm and market conditions. Generally, analysts evaluate the company based on its financial performance, growth prospects, and competitive positioning within the specialty finance and healthcare sectors. Key valuation metrics include price-to-earnings ratio, price-to-book ratio, and dividend yield (though SWKH currently does not offer a dividend).
What are the main risks for SWKH?
SWK Holdings Corporation faces several risks inherent in its business model and the industries it serves. Economic downturns can affect the ability of life science companies to repay financing, impacting SWKH's revenue and profitability. Regulatory changes in the healthcare industry can also pose risks, potentially affecting the profitability of investments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on the provided company profile and financial data.
- Analyst consensus and competitor data may not be comprehensive due to limited source information.